Effects of nebulized epinephrine in association with hypertonic saline for infants with acute bronchiolitis: A systematic review and meta-analysis.
adrenaline
child
hypertonic
saline solution
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
10
11
2021
accepted:
06
02
2022
entrez:
5
5
2022
pubmed:
6
5
2022
medline:
6
5
2022
Statut:
epublish
Résumé
Nebulized epinephrine and hypertonic saline have been extensively studied in infants with acute bronchiolitis, with conflicting results. To evaluate the efficacy on length of stay (LOS), clinical severity scores (CSS), oxygen saturation (SaO This is a systematic review and meta-analysis. Outcomes were represented by mean differences (MD) or standard mean differences (SMD) and 95% confidence intervals (CIs) were utilized. Eighteen trials were systematically selected and 16 of them contributed to the meta-analysis (1756 patients). Overall, a modest but significant positive impact was observed of the combination therapy on LOS (MD of -0.35 days, 95% CI -0.62 to -0.08, Low-quality evidence from this systematic review suggests that nebulized epinephrine plus HS may be considered as a safe and efficient therapy for decreasing LOS and CSS in infants with acute bronchiolitis, especially in those who require hospitalization for more than 48 h.
Sections du résumé
Background
UNASSIGNED
Nebulized epinephrine and hypertonic saline have been extensively studied in infants with acute bronchiolitis, with conflicting results.
Aims
UNASSIGNED
To evaluate the efficacy on length of stay (LOS), clinical severity scores (CSS), oxygen saturation (SaO
Materials & Methods
UNASSIGNED
This is a systematic review and meta-analysis. Outcomes were represented by mean differences (MD) or standard mean differences (SMD) and 95% confidence intervals (CIs) were utilized.
Results
UNASSIGNED
Eighteen trials were systematically selected and 16 of them contributed to the meta-analysis (1756 patients). Overall, a modest but significant positive impact was observed of the combination therapy on LOS (MD of -0.35 days, 95% CI -0.62 to -0.08,
Conclusion
UNASSIGNED
Low-quality evidence from this systematic review suggests that nebulized epinephrine plus HS may be considered as a safe and efficient therapy for decreasing LOS and CSS in infants with acute bronchiolitis, especially in those who require hospitalization for more than 48 h.
Identifiants
pubmed: 35509393
doi: 10.1002/hsr2.598
pii: HSR2598
pmc: PMC9059211
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e598Informations de copyright
© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Pediatrics. 2021 May;147(5):
pubmed: 33893229
Am Rev Respir Dis. 1992 Jan;145(1):106-9
pubmed: 1731571
Front Pharmacol. 2017 Jun 22;8:396
pubmed: 28690542
Isr Med Assoc J. 2006 Mar;8(3):169-73
pubmed: 16599051
Cochrane Database Syst Rev. 2020 Dec 14;12:CD012965
pubmed: 33316083
J Infect Dis. 2020 Oct 7;222(Suppl 7):S672-S679
pubmed: 31541233
BMC Pediatr. 2015 Sep 10;15:115
pubmed: 26357896
Pediatr Pulmonol. 2018 Aug;53(8):1089-1095
pubmed: 29893029
Turk J Pediatr. 2017;59(2):155-161
pubmed: 29276868
JPEN J Parenter Enteral Nutr. 2018 Jan;42(1):186-195
pubmed: 29388676
Pediatr Pulmonol. 2010 Jan;45(1):41-7
pubmed: 19953579
Arch Dis Child. 1978 Sep;53(9):707-9
pubmed: 718238
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Pediatrics. 2014 Jan;133(1):e8-13
pubmed: 24344111
Arch Dis Child. 2019 Jun;104(6):564-576
pubmed: 30655267
Medicine (Baltimore). 2020 Jan;99(4):e18657
pubmed: 31977855
J Pediatr. 2003 May;142(5):509-14
pubmed: 12756382
N Engl J Med. 2003 Jul 3;349(1):27-35
pubmed: 12840089
Am Rev Respir Dis. 1978 Oct;118(4):759-81
pubmed: 212970
Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):485-91
pubmed: 22697080
Cochrane Database Syst Rev. 2013 Jun 04;(6):CD004878
pubmed: 23733383
Cochrane Database Syst Rev. 2017 Dec 21;12:CD006458
pubmed: 29265171
BMC Med Res Methodol. 2014 Dec 19;14:135
pubmed: 25524443
World J Pediatr. 2017 Aug;13(4):293-299
pubmed: 28470580
Isr Med Assoc J. 2019 Feb;21(2):110-115
pubmed: 30772962
PLoS One. 2015 Nov 17;10(11):e0142847
pubmed: 26575036
N Engl J Med. 2013 Jun 13;368(24):2286-93
pubmed: 23758233
Cochrane Database Syst Rev. 2016 Feb 01;2:CD004873
pubmed: 26833493
Health Sci Rep. 2022 Apr 18;5(3):e598
pubmed: 35509393
Allergol Immunopathol (Madr). 2021 Jan 02;49(1):153-158
pubmed: 33528944
Pediatr Pulmonol. 2010 Jan;45(1):36-40
pubmed: 20014350
Pediatrics. 2015 Oct;136(4):687-701
pubmed: 26416925
Cochrane Database Syst Rev. 2014 Oct 09;(10):CD005189
pubmed: 25300167
Arch Pediatr Adolesc Med. 2009 Nov;163(11):1007-12
pubmed: 19884591
Tunis Med. 2014 Nov;92(11):674-7
pubmed: 25867149
BMJ. 2011 Apr 06;342:d1714
pubmed: 21471175
Arch Dis Child. 2014 Jun;99(6):511-5
pubmed: 24521787
Cochrane Database Syst Rev. 2011 Jun 15;(6):CD003123
pubmed: 21678340
An Esp Pediatr. 2001 Oct;55(4):355-64
pubmed: 11578545
Chest. 2003 Feb;123(2):481-7
pubmed: 12576370
J Pediatr. 2010 Oct;157(4):630-4, 634.e1
pubmed: 20646715
Paediatr Respir Rev. 2020 Apr;34:53-58
pubmed: 31054799
Am J Respir Crit Care Med. 2003 Dec 1;168(11):1277-92
pubmed: 14644923